Stay updated on Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:02:05.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating that there has been an increase in the number of participants enrolled in the Phase II trial of Nivolumab and Stereotactic Ablative Radiation Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:09.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments. Previously, this section only indicated that no information was provided.
    Difference
    42%
    Check dated 2024-05-22T21:02:32.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:01:46.000Z thumbnail image

Stay in the know with updates to Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page.